Table 2.
Studies evaluating the mutation status of BRAF and NRAS in acquired melanocytic nevi
| Study | Histology of nevi analyzed* |
BRAF mutations |
NRAS mutations |
|---|---|---|---|
| (Jafari et al., 1995) | Benign nevi | -- | 0/5 (0%) |
| (Pollock et al., 2003) | Intradermal | 37/42(88%) | -- |
| Compound | 16/23(70%) | -- | |
| (Dong et al., 2003) | Benign melanocytic nevi | 17/24(70.8%) | 0/24(0%) |
| (Saldanha et al., 2004) | Common acquired nevi | 14/16(87.5%) | 2/11(18.2%) |
| (Poynter et al., 2006) | Benign melanocytic nevi | 42/51(82.3%) | 3/51(5.9%) |
| (Ichii-Nakato et al., 2006) | Common acquired nevi | 105/120(87.5%) | -- |
| (Uribe et al., 2006) | Common acquired nevi | 16/24(66.7%) | -- |
| (Bloethner et al., 2007) | Benign melanocytic nevi | 18/30(60%) | -- |
| (J. Wu et al., 2007) | Common acquired nevi | 83/101(82.2%) | -- |
| (Venesio et al., 2008) | Compound nevi | 6/13(46.2%) | 0/13(0%) |
| Intradermal nevi | 3/6(50%) | 0/6(0%) | |
| Junctional nevi | 2/3(66.7%) | 0/3(0%) | |
| (Tschandl et al., 2013) | Control nevi | 14/25(56%) | 3/21(14.3%) |